
Prediction: Palantir Has 4 Wall Street Sell Ratings, and This Figure Will More Than Double in the Coming Months
Wall Street analysts have an overwhelming "buy" bias, with only 4.9% of the 12,319 ratings on S&P 500 stocks (as of late June) representing sell ratings.
Analysts have been bullish on artificial intelligence (AI) juggernaut Palantir Technologies due to the irreplaceability of its platforms and its recurring profits.
Though only four out of 24 Wall Street analysts rate Palantir stock the equivalent of a sell, its inexplicable valuation premium is likely to send this figure notably higher.
10 stocks we like better than Palantir Technologies ›
History has taught investors that being a long-term optimist is a smart decision. The analysts at Crestmont Research examined more than a century of rolling 20-year total returns, including dividends, for the benchmark S&P 500 and discovered that all 106 rolling 20-year periods they analyzed would have generated a positive annualized total return.
This realization that the stock market's major indexes have a propensity to climb in value over time has led to an overwhelming"buy" bias for Wall Street analysts. According to data from FactSet Insight, there were 12,319 ratings on stocks in the S&P 500, as of late June. A whopping 56.4% of these ratings were the equivalent of "buy," 38.7% were "hold," and only 4.9% were the equivalent of "sell."
Despite this buy bias on Wall Street, history also tells us that not all stocks climb in value, nor do they rise in a straight line when increasing in value over time. Although sell ratings are exceedingly rare, there's one high-flying stock, which has returned 2,130% since the end of 2022, that could be a sell rating magnet for Wall Street analysts in the coming months: Palantir Technologies (NASDAQ: PLTR).
Palantir Technologies blows away Wall Street's loftiest expectations
Based on analyst ratings aggregated by LSEG Data & Analytics (formerly Refinitiv), 24 Wall Street analysts have weighed in on Palantir Technologies. Five rate it as the equivalent of a strong buy or buy, 15 list it as a hold or market perform, and four have it rated the equivalent of underperform or sell.
There's a reason analysts have been overwhelmingly bullish on Palantir -- and it has to do with more than the historical precedent of Wall Street's major stock indexes rising over long periods.
To begin with, analysts appreciate Palantir's unique positioning and sustainable moat. The company's two premier artificial intelligence (AI) - and machine learning-driven operating platforms, Gotham and Foundry, have no large-scale competitors. When Palantir lands a client, it tends to hang onto them.
To build on this point, Palantir is capable of producing highly predictable operating cash flow quarter after quarter. Its Gotham platform aids federal governments with military mission planning and execution, as well as data collection and analytics. The contracts signed for this segment commonly stretch out four or five years. Meanwhile, Foundry is a subscription-based model geared at businesses that often leads to high retention rates.
Palantir also dazzled Wall Street by flipping into the recurring profit column ahead of expectations. While Gotham accounts for the lion's share of its operating income, shifting to recurring profits demonstrates the validity of Palantir's AI-focused, dual-platform model.
To round things out, Wall Street analysts have likely anticipated strength in Palantir's operations following Donald Trump's November victory and Republicans winning both houses of Congress. Historically, Republicans haven't been shy about increasing defense spending. President Trump's focus on internal AI innovation and protecting America's security interests plays right into the hands of Gotham.
Prediction: Wall Street sell ratings on Palantir are about to become commonplace
But there's also the real possibility Wall Street's love affair with Palantir is going to end sooner rather than later. Even though Palantir offers a sustainable moat and, thus far, a sales growth rate that's hovered in the 25% to 35% range on an annual basis, there are a few headwinds Wall Street analysts won't be able to overlook.
Firstly, there's the realization that all game-changing innovations need ample time to mature. Despite all the hoopla surrounding artificial intelligence and AI stocks like Palantir, there's a strong possibility that investors have, once again, overestimated how quickly this new technology will gain mainstream adoption and/or utility.
If an AI bubble were to form and burst, Palantir stock wouldn't be immune. While its multiyear government contracts (via Gotham) and subscriptions (via Foundry) would insulate its revenue from falling off a cliff, investor sentiment during bubble-bursting events would make Palantir stock a target.
Secondly, there's only so much growth that can be squeezed out of Gotham with a limited list of potential clients. Though it's great having the U.S. government as a core customer, only the U.S. and its immediate allies can access this sensitive platform. As time passes, this is going to limit Gotham's growth potential.
But the No. 1 reason sell ratings on Palantir can more than double in the coming months is the company's inexplicable valuation.
To be clear, I absolutely do believe Palantir stock is worthy of a valuation premium. Any company that can deliver double-digit sales growth with a sustainable moat deserves a valuation premium, relative to its peers. But there's a limit as to how far this premium can carry a stock.
PLTR PS Ratio data by YCharts. PS Ratio = price-to-sales ratio.
Prior to the bursting of the dot-com bubble in the late 1990s and early 2000s, leaders like Microsoft, Cisco Systems, and Amazon peaked at price-to-sales (P/S) ratios ranging from 31 to 43. Throughout history, this P/S ratio range of 30 to 40 has commonly served as a top for market-leading businesses on the cutting edge of a next-big-thing innovation.
As of the closing bell on July 9, Palantir Technologies' P/S ratio clocked in at 114! That's one hundred and fourteen, with no missing decimal points! No megacap stock in the history of Wall Street has ever been able to maintain a premium P/S multiple of this magnitude. Even if Palantir were able to grow its sales by 30% annually through 2029, its P/S ratio would still be 31 heading into the turn of the decade. This is how far out of whack Palantir's valuation is at the moment.
The vast majority of hold ratings on Palantir have attached price targets that are significantly below the $143.13 per share it closed at on July 9. I believe these analysts will struggle to justify any additional increase in their respective price target given Palantir's inexplicable P/S premium.
It's simply a matter of time before the valuation-based sell ratings from Wall Street begin to stream in.
Should you invest $1,000 in Palantir Technologies right now?
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!*
Now, it's worth noting Stock Advisor 's total average return is1,047% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 7, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Cisco Systems, FactSet Research Systems, Microsoft, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
37 minutes ago
- Globe and Mail
Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
"Multiple System Atrophy Clinical Trials" Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others. (Albany, United States) 'Multiple System Atrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market. As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details Request for sample report to know in detail about drugs and companies in pipeline @ Multiple System Atrophy Pipeline Outlook Some of the key takeaways from the Multiple System Atrophy Pipeline Report: Multiple System Atrophy Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years. Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others, are developing therapies for the Multiple System Atrophy treatment Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years. are expected to have a significant impact on the Multiple System Atrophy market in the coming years. In May 2025, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company'), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy. In February 2025, H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA). In December 2024, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on creating disease-modifying therapies for neurodegenerative disorders, announced that the final participant in its ATH434-201 Phase 2 trial has completed the study. This randomized, double-blind, placebo-controlled trial targets early-stage multiple system atrophy (MSA). With this milestone reached, topline results are anticipated by late January or early February 2025. Multiple System Atrophy Overview Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by Multiple System Atrophy autonomic dysfunction, Multiple System Atrophy parkinsonism, and Multiple System Atrophy cerebellar ataxia. Multiple System Atrophy symptoms often include orthostatic hypotension, urinary incontinence, tremors, bradykinesia, muscle rigidity, gait imbalance, and coordination problems. Multiple System Atrophy diagnosis typically relies on clinical evaluation supported by MRI findings, which may show putaminal or cerebellar atrophy, although no definitive test exists. Multiple System Atrophy pathology reveals glial cytoplasmic inclusions containing alpha-synuclein, distinguishing it from similar disorders. Multiple System Atrophy progression is usually rapid, leading to severe disability within a few years of onset. Multiple System Atrophy treatment remains symptomatic, aiming to manage blood pressure fluctuations, motor symptoms, and urinary issues. While Multiple System Atrophy levodopa responsiveness is often poor compared to Parkinson's disease, some patients may experience temporary benefit. Multiple System Atrophy prognosis is generally poor, with an average survival of 6 to 10 years post-diagnosis. Ongoing Multiple System Atrophy research explores neuroprotective agents and disease-modifying therapies. Multiple System Atrophy awareness is essential for early recognition and multidisciplinary care to optimize patient quality of life. Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment- Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include: NM-402: Neuramedy Co.,Ltd Neuramedy Co.,Ltd PMN442: ProMIS Neurosciences ProMIS Neurosciences ENT-01: Enterin Inc. Enterin Inc. NC-2500: Nippon Chemiphar Nippon Chemiphar CS10BR05: CORESTEM, Inc CORESTEM, Inc AAV2-GDNF: Brain Neurotherapy Bio, Inc. Brain Neurotherapy Bio, Inc. KM-819: Kainos Medicines Kainos Medicines ATH434: Alterity Therapeutics Alterity Therapeutics Lu AF82422: H. Lundbeck A/S H. Lundbeck A/S Verdiperstat: Biohaven, Ltd Biohaven, Ltd Ampreloxetine: Selecta Biosciences Inc Selecta Biosciences Inc ION464: Ionis Pharmaceuticals, Inc Multiple System Atrophy Route of Administration Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Multiple System Atrophy Molecule Type Multiple System Atrophy Products have been categorized under various Molecule types, such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Multiple System Atrophy Pipeline Therapeutics Assessment Multiple System Atrophy Assessment by Product Type Multiple System Atrophy By Stage and Product Type Multiple System Atrophy Assessment by Route of Administration Multiple System Atrophy By Stage and Route of Administration Multiple System Atrophy Assessment by Molecule Type Multiple System Atrophy by Stage and Molecule Type DelveInsight's Multiple System Atrophy Report covers around 22+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies Some of the key companies in the Multiple System Atrophy Therapeutics Market include: Key companies developing therapies for Multiple System Atrophy are - Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others. Multiple System Atrophy Pipeline Analysis: The Multiple System Atrophy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment. Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies Multiple System Atrophy Pipeline Market Drivers Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market. Multiple System Atrophy Pipeline Market Barriers However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth. Scope of Multiple System Atrophy Pipeline Drug Insight Coverage: Global Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials Table of Contents 1. Multiple System Atrophy Report Introduction 2. Multiple System Atrophy Executive Summary 3. Multiple System Atrophy Overview 4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment 5. Multiple System Atrophy Pipeline Therapeutics 6. Multiple System Atrophy Late Stage Products (Phase II/III) 7. Multiple System Atrophy Mid Stage Products (Phase II) 8. Multiple System Atrophy Early Stage Products (Phase I) 9. Multiple System Atrophy Preclinical Stage Products 10. Multiple System Atrophy Therapeutics Assessment 11. Multiple System Atrophy Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Multiple System Atrophy Key Companies 14. Multiple System Atrophy Key Products 15. Multiple System Atrophy Unmet Needs 16 . Multiple System Atrophy Market Drivers and Barriers 17. Multiple System Atrophy Future Perspectives and Conclusion 18. Multiple System Atrophy Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight


CTV News
43 minutes ago
- CTV News
Manitobans feeling financial strain: survey
Winnipeg Watch CTV's Katherine Dow talked with licensed insolvency trustee Brad Milne about how Canadians are feeling the strain of recent interest rate pauses.

CTV News
43 minutes ago
- CTV News
Toronto's primary Ornge air ambulance back in service, second chopper still unavailable
An ORNGE air ambulance service helicopter sits outside a hanger at their base at Billy Bishop Airport in Toronto on Tuesday, December 13, 2022. THE CANADIAN PRESS/Chris Young Toronto's primary Ornge ambulance helicopter is back in service after it had been grounded for upkeep. Last week, supply chain issues caused in part by U.S. tariffs had resulted in maintenance delays. In a statement to CTV News on Monday, Ornge said its primary Toronto-based helicopter has returned to service, while a second one will not fly until July 18. 'Progress continues on the required maintenance for Toronto's air ambulance helicopters. During the weekend maintenance, contingency plans were activated to maintain coverage,' the statement read. It said from July 10 to 13, Ornge crews performed about 86 patient transports in their typical Toronto response area, requiring air and land ambulance resources from other bases to be deployed as needed. 'This approach to dispatch will continue as we work toward a full resumption of helicopter operations at the Billy Bishop Toronto City Airport, which remains our top priority,' Monday's statement added. Ornge has helicopters in Sudbury, London, and Ottawa. A source told CTV News Toronto last week that staff were informed about the status of the two helicopters in a letter from Ornge's chief aviation officer, Peter Cunnington. In the letter, Cunnington said Ornge has been experiencing 'unusually high demand for maintenance' across its AW139 fleet and that the global supply chain delays 'have caused significant extensions to maintenance timelines.' 'Despite these challenges, our maintenance teams have been working tirelessly to meet operational demands. Unfortunately, setbacks related to supply issues from our primary vendors continue to impact our progress,' the letter read. 'Manufacturers have cited ongoing disruptions tied to raw material shortages caused by U.S. tariffs and the war in Ukraine.' As of May, Ornge helicopters have airlifted 1,684 patients to Ontario hospitals. With files from CP24's Bryann Aguilar